Thread by @leticiakawano

1/ ACTT-1 preliminary results
🔴1:1 randomization stratified by dz severity & center - Remdesivir vs placebo (total sample: 1,063)
🔴1ary outcome: *time* to recovery (time frame: 28d)

nejm.org/doi/full/10.10… @NEJM

2/
🔴By the time the DSMB recommended for the end of the study, recruitment had finished. Only 391/340 pts in the Remdesivir/placebo group had 28d complete data.
🔴But the analysis of the population included 1,059 for whom researchers had at least some postbaseline data

3/ Pts were not too old (mean age 58), median time PSO ~9 days, with moderate to severe #covid19

4/ Pts on remdesivir had a shorter time to recovery
rate ratio for recovery, 1.32; 95% confidence interval
[CI], 1.12 to 1.55; P<0.001; 1059 patients.

5/ On the pre-specified subgroup analysis on the number of days post-symptom onset (PSO) - Remdesivir *seems* to be equally effective for "early" or late covid19.

6/ HR of 0.70 [95%CI 0.47 - 1.04] for mortality. *Possibly* remdesivir would have scored for mortality if it had recruited a larger sample.
AE data reassuring - see suppl.

#covid19

7/ Last tweet:
Results are consistent with a truly positive effect of remdesivir on #COVIDー19

Its magnitude of effect is especially significant if we consider its context: the (high) incidence of covid19 worldwide (in Brazil for ex) that will need hospital admission/treatment